Doctors at Sahyadri Hospitals perform 6-hour-long hand re-implantation surgery

Pune: In an extremely rare incident, Sahyadri Hospitals in Pune has achieved a medical milestone by successfully conducting an arm-level re-implantation on Diwali, the festival of triumph and homecoming. 

This extraordinary feat was accomplished by a skilled team of medical professionals led by Dr Sumit Saxena, a plastic and cosmetic surgeon and consultant at Sahyadri Super Speciality Hospital, Hadapsar, Pune.

Also Read:Sahyadri Hospital doctors perform mechanical thrombectomy on 62-year-old heart attack patient

The patient, Mr Ramesh (name changed), had a life-altering accident while traveling through Dive Ghat on a bike. His right upper limb was amputated at the arm level when he was struck by a truck in the early hours of the day. Promptly brought to Sahyadri Hospital Hadapsar branch for treatment, Dr Sumit Saxena immediately took charge of the situation.

In a marathon six-hour surgery, Dr. Saxena and his team undertook the challenging task of salvaging the severed limb. Dr. Saxena emphasized the critical nature of the operation, stating, “Time is the key in these surgeries, and all major structures, including vessels, nerves, muscles, tendons, and bones, were repaired within the crucial six-hour window. The patient’s condition was critical due to significant blood loss.”

The surgery was particularly complex due to the high level of amputation, posing risks to life and requiring a meticulous approach. Dr. Saxena acknowledged the technical difficulties involved, stating, “Recovery becomes poor at the higher level of amputation, and there is a threat to life because of chances of reperfusion injury. A close watch is required postoperatively.”

“This type of surgery is unique in nature, rarely performed, and even more rarely successful,” remarked Dr. Saxena. “It is critical to salvage the patient after these reimplantation, making them truly rare cases.”

The patient, Mr. Ramesh, was discharged after a few weeks when he finally recovered. Given the additional fractures he sustained, he is currently under observation. Remarkably, the patient demonstrated a swift recovery within 15 days, a testament to the expertise and comprehensive care provided by Sahyadri Hospitals.

Despite the festive occasion of Diwali, the medical team at Sahyadri Hospital, Hadapsar, led by Dr. Saxena, demonstrated unwavering commitment by foregoing personal celebrations to prioritize the patient’s well-being. The successful outcome of this complex surgery not only prevented a potential disaster for Mr. Ramesh but also exemplified the true essence of Diwali – the triumph of light over darkness.

This successful arm level reimplantation highlights Sahyadri Hospitals’ position as a center of medical expertise, pushing the boundaries of what is considered possible in the field of reconstructive surgery.

Dr Saxena expressed his gratitude to the dedicated team that contributed to the success of the surgery, including Dr Tapadia (Orthopedic), Dr Rupa Abraham (Anesthetist), Dr Inayat (Orthopedic), Dr Manish (Assistant), Brother Dharmendra, Sister Priyanka, and all ICU and ward staff. Sahyadri Hospital provided crucial support in the emergency to safeguard the patient’s interests.

Powered by WPeMatico

NPPA fixes Retail Prices of 19 Formulations, Details

New Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA), the Ministry of Chemicals and Fertilizers, Government of India, has fixed the retail price of 19 formulations, including pain killers, anticancer drugs, and those used to treat high blood pressure.

This came in line with the decision of the 119th Authority meeting dated 15.12.2023, where the authority discussed the new drug applications for price fixation under para 5 and 15 of the drugs prices control order, 2013 (DPCO 2013).

These include Ravenbhel Healthcare/Cadila Pharmaceutical’s fixed-dose combination drug Bilastine and Montelukast Tablets, Pure and Cure Healthcare /Cipla’s film-coated bi-layered tablet containing Metoprolol Succinate Extended Release and Cilnidipine, Akums Drugs and Pharmaceuticals/Apex Laboratories’ Aceclofenac plus Paracetamol plus Serratiopeptidase Tablet, etc.

Furthermore, the retail price of the anticancer drug Trastuzumab 150mg, manufactured and marketed by Hetero Biopharma and Mankind Pharma, has also been set.

This comes in the exercise of the powers conferred by paragraphs 5, 11, and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 5249(E) dated 11th November 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority has fixed the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit, and name of manufacturer and marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof,

Sl. No

.

Name of the

Formulation / Brand Name

Strength

Unit

Manufacturer &

Marketing Company

Retail

Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

1

Bisoprolol Fumarate & Amlodipine tablet

Each film coated tablet contains:

Bisoprolol Fumarate IP 2.5mg

Amlodipine Besylate IP Eq.

to Amlodipine 5mg

1

Tablet

M/s Swiss Garnier Biotech Private Limited / M/s Zydus Healthcare

Limited

6.74

2

Aceclofenac + Paracetamol + Serratiopeptid ase Tablet

Each film coated tablet contains:

Aceclofenac IP 100mg, Paracetamol IP 325mg Serratiopeptidase IP 15mg (As enteric coated granules eq. to 30000 enzyme activity unity of

serratiopeptidase)

1

Tablet

M/s Akums Drugs & Pharmaceuticals Ltd. /M/s Apex Laboratories Private Limited

8.00

3

Povidone Iodine Gargle

Povidone Iodine Gargle Composition:

Povidone-Iodine IP 2% w/v (Available Iodine

0.2w/v)

1 ml

M/s Stedman Pharmaceuticals Pvt. Ltd.

1.93

Sl. No

.

Name of the Formulation / Brand Name

Strength

Unit

Manufacturer & Marketing Company

Retail Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

4

Amoxycillin + Potassium Clavulanate Tablets IP

Each film coated tablet contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 875mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 125mg

1

Tablet

M/s Theon Pharmaceuticals Ltd. / M/s J.B. Chemicals & Pharmaceuticals Ltd.

40.03

5

Bilastine and Montelukast Tablets

Each film coated tablet contains: Montelukast Sodium IP Eq. to Montelukast 10mg Bilastine 20mg

1

Tablet

M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Cadila Pharmaceuticals Ltd.

13.02

6

Telmisartan and Metoprolol Succinate (ER) Tablet

Each film coated bilayered tablet contains: Telmisartan IP 40mg Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate 50mg (as extended release form)

1

Tablet

M/s Pure and Cure Healthcare Pvt. Ltd. / M/s La Renon Healthcare Pvt. Ltd.

13.39

7

Metoprolol Succinate Extended Release & Cilnidipine Tablet

Each film-coated bilayered tablet contains: Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate IP 25mg (As Extended release form) Cilnidipine IP 10mg

1

Tablet

M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Cipla Limited

9.12

8

Metoprolol Succinate Extended Release & Cilnidipine Tablet

Each film-coated bilayered tablet contains: Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate 50mg (As Extended release form) Cilnidipine IP 10mg

1

Tablet

M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Cipla Limited

10.21

9

Trastuzumab 150mg

Combipack of Each pack contains:

Vial-1

Lyophilized Powder for concentrate for solution for Intravenous Infusion, Multi-use vial Composition: Trastuzumab (rDNA Origin) IH (Active ingredient) 150mg, α,α-Trehalose Dihydrate

1 Vial

M/s Hetero Biopharma Limited / M/s Mankind Pharma Limited

15817

.49

Sl. No

.

Name of the Formulation / Brand Name

Strength

Unit

Manufacturer & Marketing Company

Retail Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

USP (as Lyoprotectant) 136.2mg

L-Histidine Hydrochloride Monohydrate EP (as buffering agent) 3.36mg

L-Histidine USP (as buffering agent) 2.16mg Polysorbate 20 IP (as surfactant) 0.6mg

Vial -2

Bacteriostatic Water for Injection 10 ml

Single use vial Composition:

Benzyl Alcohol IP 1.1%

V/V Water for Injection

10

Sucralfate, Metronidazole and Lignocaine Hydrochloride

Cream

Composition:Sucralfate IP 7.0% w/wMetronidazole IP 1.0% w/w Lignocaine Hydrochloride IP 4.0%

w/wCream base q.s.

Per Gram

M/s Stedman Pharmaceuticals Pvt. Ltd.

4.45

11

Bisoprolol Fumarate and Telmisartan Tablets

Each film coated tablet contains:

Bisoprolol Fumarate IP 2.5 mg

Telmisartan IP 40 mg

1

Tablet

M/s Ravenbhel Healthcare Pvt Ltd / M/s La Renon Healthcare Pvt

Ltd

9.73

12

Bisoprolol Fumarate and Telmisartan Tablets

Each film coated tablet contains:

Bisoprolol Fumarate IP 5 mg

Telmisartan IP 40 mg

1

Tablet

M/s Ravenbhel Healthcare Pvt Ltd / M/s La Renon Healthcare Pvt

Ltd

11.22

13

Bisoprolol Fumarate and Telmisartan Tablets

Each film coated bilayered tablet contains:

Bisoprolol Fumarate IP 2.5 mg

Telmisartan IP 40 mg

1

Tablet

M/s Mascot Health Series Pvt. Ltd. / M/s Zydus

Healthcare Ltd.

9.73

14

Bisoprolol Fumarate and Telmisartan Tablets

Each film coated bilayered tablet contains:

Bisoprolol Fumarate IP 5 mg

Telmisartan IP 40 mg

1

Tablet

M/s Mascot Health Series Pvt. Ltd. / M/s Zydus

Healthcare Ltd.

11.22

15

Norethisterone Acetate

Each Film Coated Controlled Release tablet

1

Tablet

M/s Akums Drugs &

15.80

Sl. No

.

Name of the Formulation / Brand Name

Strength

Unit

Manufacturer & Marketing Company

Retail Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

Controlled Release Tablet

contains:

Norethisterone Acetate BP 10mg

Pharmaceuticals Ltd. / M/s Group Pharmaceuticals

Ltd.

16

Sodium Alginate, Sodium Bicarbonate & Calcium Carbonate Oral

Suspension

Each 5 ml contains: Sodium Alginate IP 250mg Sodium Bicarbonate IP 133.5mg

Calcium Carbonate IP 80mg

1 ml

M/s Skymap Pharmaceuticals Pvt. Ltd.

0.90

17

Sodium Alginate, Sodium Bicarbonate & Calcium Carbonate Oral

Suspension

Each 5 ml contains: Sodium Alginate IP 250mg Sodium Bicarbonate IP 133.5mg

Calcium Carbonate IP 80mg

1 ml

M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Glensmith Labs Pvt. Ltd.

0.90

18

Sodium Alginate, Sodium Bicarbonate & Calcium Carbonate Oral Suspension

Each 5 ml contains: Sodium Alginate IP 250mg Sodium Bicarbonate IP 133.5mg Calcium Carbonate IP 80mg

1 ml

M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Jagsonpal Pharmaceuticals Ltd.

0.90

19

Albendazole & Ivermectin Tablets

Each uncoated chewable tablet contains: Albendazole IP 400mg Ivermectin IP 6mg

1 Tablet

M/s IBN Herbals (A unit of Curetech Formulation (P) Ltd.) / M/s Indoco Remedies

Limited

24.63

The notice further added,

(a) The manufacturer of the above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6)of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from the date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to the State Drug Controller and dealers.

(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(e) The above-mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned above i.e. who has applied for the same by submitting Form- I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g) Consequent to the fixation of the retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer and marketing Companies specified in the corresponding entries in Columns (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.

To view the official notice, click the link below:

Powered by WPeMatico

Submit PK-PD data of 3 cohorts for 7 days: CDSCO Panel Tells Shilpa Medicare on Ondansetron ER Inj Suspension IM study

New Delhi: Regarding the conduction of a study to evaluate the efficacy and safety of Ondansetron Extended-Release Injectable Suspension Intramuscular when compared to Ondansetron IM Injection for the prevention of chemotherapy-induced Nausea and Vomiting (CINV) in patients receiving moderate and highly emetogenic chemotherapy, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined Shilpa Medicare that the firm should submit pharmacokinetic and pharmacodynamic (PK-PD data) of 3 cohorts for 7 days, with a minimum effective concentration of the drug and QT interval data at Tmax.

This came after Shilpa Medicare presented the proposal for a grant of permission to conduct a Phase-III clinical trial titled “A Phase-III, Randomized, Multicentre, Double-Blind, Parallel Group, Prospective, NonInferiority Study to Evaluate the Efficacy and Safety of Ondansetron ExtendedRelease Injectable Suspension Intramuscular When Compared to Ondansetron IM Injection for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Moderately and Highly Emetogenic Chemotherapy” of the drug Ondansetron Extended-release (ER) intramuscular Injectable suspension 100mg/1ml along with Phase-III protocol (Protocol No. NV-05-1543-2023 Version No. 1.0 dated 29th Aug 2023) before the committee.

Ondansetron is in a class of medications called serotonin 5-HT3 receptor antagonists. It works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting

Ondansetron is used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. Ondansetron is in a class of medications called serotonin 5-HT3 receptor antagonists. It works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting.

It is hypothesized that ondansetron blocks nausea and vomiting by 5-HT3 receptor antagonism at two specific sites: (i) centrally, in the area postrema/NTS; and (ii) peripherally on vagus nerve terminals. The absence of other pharmacological effects of ondansetron ensures an absence of side effects.

At the recent SEC meeting for Oncology and Hematology held on 21 and 22 December 2023, the expert panel reviewed the proposal to conduct a Phase-III clinical trial titled “A Phase-III, Randomized, Multicentre, Double-Blind, Parallel Group, Prospective, NonInferiority Study to Evaluate the Efficacy and Safety of Ondansetron ExtendedRelease Injectable Suspension Intramuscular When Compared to Ondansetron IM Injection for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Moderately and Highly Emetogenic Chemotherapy” presented by Shilpa Medicare.

In the above meeting, the firm informed that the Ondansetron extended-release (ER) intramuscular injectable suspension 100mg/1ml is not yet approved anywhere.

The committee noted that the justification submitted by the firm was not found scientifically adequate.

After detailed deliberation, the committee recommended that the firm submit PK-PD data of 3 cohorts for 7 days, with a minimum effective concentration of the drug and QT interval data at Tmax to CDSCO for further review by the committee.

Also Read: Justify Clinical Relevance of Higher Strength of Caroverine Capsules: CDSCO Panel Tells Lincoln Pharma

Powered by WPeMatico

Vacancies For SR Post At JIPMER: Walk-In Interview, Check All Details Here

Puducherry: The Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER Puducherry) has released vacancies for the post of Senior Resident on an ad hoc basis in different departments in this institute. 

JIPMER became an institution of national importance under the Ministry of Health and Family Welfare, Government of India in the year 2008. JIPMER offers various undergraduate and postgraduate medical courses. Located in Pondicherry, JIPMER is also a fully functional hospital that provides medical treatments to patients from all over the world. It has about 200 faculty members 3,000 staff and 360 resident physicians.

JIPMER Puducherry Vacancy Details:

Total no of vacancies: 05

The vacancies are in the Departments of Anaesthesiology, Cardiothoracic and Vascular Surgery, and Neurosurgery.

Date of walk-in-Interview:- 12th January 2024.

Venue: Room No.104, GROUND FLOOR, ADMINISTRATIVE BLOCK, JIPMER, PUDUCHERRY-06

For more details about Qualifications, Age, Pay Allowance, and much more, click on the given link:

https://medicaljob.in/jobs.php?post_type=&job_tags=jipmer&location=&job_sector=all

Eligible Candidates (How to Apply):-

(i) Filled in application & Bio-Data in the prescribed format (appended);

(ii) Original Certificates with one set of Self-attested copy thereof and;

(iii) Copy of the printout of fees paid through online.

List of Original Certificates

1. Age proof certificate (Birth certificate/10th/12th Mark sheet)

2. MBBS/MD/MS/DNB/DM/M.Ch Provisional/Degree certificate

3. MBBS/MD/MS/DNB/DM/M.Ch Registration certificate

4. Internship Completion Certificate.

5. Conduct and Character certificate from the Institution/College where he/she completed his/her PG study. 6. Residence certificate issued by Revenue authority not below the rank of Tahsildar / Dy.Tahsildar or Aadhar card/voter ID/Passport.

7. The candidates who are in service in any Govt. Hospitals/Institutions are required to submit a “No Objection Certificate” from the present employer.

8. Community Certificate (If applicable) – fee purpose only. Candidates are advised NOT TO SEND HARD COPY of the application with documents by postal/courier/by hand.

The crucial date for determining eligibility regarding age and educational qualification will be on 12-01-2024.

To be eligible for selection, the candidate should complete all the requirements for the qualifying degree (e.g. passing the examination and completing the mandatory period of work, if any) by 12-01-2024.

Those who does not fulfill any of the above conditions need not apply. Mere permission to appear in the examination or interview does not imply any determination of final eligibility.

Powered by WPeMatico

India orders new drug-making standards after overseas deaths

New Delhi: Indian pharmaceutical companies must meet new manufacturing standards this year, according to a government notification released on Saturday, although small companies have asked for a delay, citing their debt load.

Jolted by a string of overseas deaths linked to Indian-made drugs since 2022, Prime Minister Narendra Modi’s government has stepped up scrutiny of pharmaceutical factories to clean up the image of the $50 billion industry.

“The manufacturer must assume responsibility for the quality of the pharmaceutical products to ensure that they are fit for their intended use, comply with the requirements of the licence and do not place patients at risk due to inadequate safety, quality or efficacy,” said the notification, dated Dec. 28.

Companies must market a finished product only after getting “satisfactory results” on tests of the ingredients and retain a sufficient quantity of the samples of intermediate and final products to allow repeated testing or verification of a batch, it says.

The health ministry said in August that inspections of 162 drug factories since December 2022 found an “absence of testing of incoming raw materials”. It said fewer than a quarter of India’s 8,500 small drug factories met international drug manufacturing standards set by the World Health Organization (WHO).

The notification said those concerns must be addressed by large drugmakers within six months and small manufacturers in 12 months. Small companies had asked for the deadline to be extended, warning that investments required to meet the standards would shut down nearly half of them because they are already heavily indebted.

The WHO and other health authorities have linked Indian cough syrups to the deaths of at least 141 children in Gambia, Uzbekistan and Cameroon.

Read also: Maiden Pharma denies tampering with tests in probe of cough syrup deaths

Powered by WPeMatico

Suspected Spurious Drugs Case: Centre orders CBI probe into supply of drugs in Govt Hospitals

New Delhi: The Union Home Ministry ordered a Central Bureau of Investigation (CBI) inquiry into the supply of substandard medicines in Delhi government hospitals on Friday. Delhi Health Minister Saurabh Bharadwaj welcomed the move and demanded the immediate suspension of the health department’s secretary.

With a CBI inquiry being ordered into the supply of substandard medicines in Delhi government hospitals, Delhi Health Minister Saurabh Bharadwaj on Friday said of the “43 samples” collected from three hospitals, only five were declared “not of standard quality”. At a press conference in the national capital, he said the official report used many times the terms “NSQ” or “not of standard quality”. It is “nowhere mentioned (in the report) that the drugs are fake, counterfeit, poison, spurious”.

“You cannot write it officially like that as it wasn’t so,” he said.

Delhi Health Minister Saurabh Bharadwaj on Friday welcomed the Central Bureau of Investigation (CBI) inquiry into the alleged supply of substandard medicines to Delhi government-run hospitals and demanded the immediate suspension of the health department’s secretary. 

The inquiry by the CBI was ordered by the Union home ministry following a recommendation of Delhi Lieutenant Governor V K Saxena in this regard. 

Also Read:Fake Lab tests, Ghost patients at Delhi Mohalla clinics: LG calls for CBI inquiry

“I had given directions for carrying out an audit of medicines immediately after assuming office in March last year but the (Delhi government) health secretary did not follow the directions. I welcome the CBI inquiry into the matter, but why is the Centre shielding the official. He should be immediately suspended,” Bharadwaj said.

Saxena had in December recommended the CBI probe into the supply of drugs that had allegedly “failed quality standard tests” and had the “potential of endangering lives”.

Later, the Delhi government’s Directorate of Vigilance had wrote to the home ministry, requesting it for the probe.

The Union Home Ministry has ordered a Central Bureau of Investigation (CBI) inquiry into the alleged supply of substandard medicines in Delhi government hospitals and if the drugs were also distributed through mohalla clinics, sources said on Friday.

The CBI probe was ordered following a recommendation by Delhi Lt Governor VK Saxena in December.

Bharadwaj also sought to blame the BJP on the issue and alleged that the saffron party is “spreading rumours” about these drugs being “fake and spurious” though the medicines were “neither spurious nor fake, they just did not meet some of the standards (of testing)”.

The health minister’s office later issued a statement in which it alleged that “the BJP is spreading lies about fake medicines in Delhi to influence the upcoming elections”.

Responding to the allegations, the BJP’s Delhi unit chief Virendra Sachdeva questioned why Bhardwaj “remained silent” although he had claimed to have been aware of the issues related to medicines and pathological tests in March 2023 itself.

Earlier in the day, Bharadwaj welcomed the CBI inquiry into the alleged supply of substandard medicines in Delhi government-run hospitals and demanded the immediate suspension of the health department’s secretary.

At his press conference, he sought to allay the “fear” in the minds of crores of citizens of Delhi about the quality of medicines supplied in city government-run hospitals and assured them that the drugs are neither spurious nor counterfeit, as claimed by the BJP.

All medicines were “found to contain genuine salt”, there was no other salt or any fake salt, the minister said citing the report.

The test report of medicine samples says it was not of standard quality and the reason for that was cited as dissolution, ie, the time a medicine takes to dissolve in the stomach, the minister told reporters.

“The companies which supply drugs to Delhi government hospitals also supply medicines to hospitals of the central government and other states,” Bharadwaj said.

Testing drug samples from time to time is “normal protocol” which is a continuous process and, if a medicine sample doesn’t meet standards, the whole “batch of drugs is returned” and payment of the firm is “withheld”, the minister said.

Even as per CPA (Central Procurement Agency) data, 12 of 281 samples in 2022-23 and 20 of 651 in 2023-24 were “found to be ‘not of standard’, and this is a normal practice”, Bharadwaj said.

During the press conference at the Delhi Secretariat, he also alleged that the BJP and a “constitutional office” aided in “planting news that these medicines are fake”.

“I am not a pharmacist, I am not a doctor. However, when I looked carefully at the test reports of the samples mentioned in the Vigilance department report, which was sent to the CBI, I spoke to many pharmacists, and some private pharmacists, private doctors, and came to know some very surprising things,” he said.

The Delhi health minister also mentioned the names of the drugs mentioned in the report — “pantoprazole gastro-resistant tablets IP 40 mg, amlodipine tablets IP 5 mg, levetiracetam tablets IP 500 mg, cephalexin capsules IP 500 mg, and dexamethasone tablets IP 4 mg”.

“It is just like the vicious campaign that was run by some BJP leaders in 2019 that the water of Delhi was ‘poisonous’ but no BJP leader left Delhi in 2019. Though their relatives and friends seek treatment in these Delhi government hospitals, they are still lying about the medicines supplied there,” he said.

Powered by WPeMatico

Health Bulletin 6/January/2024

Here are the top health stories for the day:

12 Covid deaths, 774 fresh cases reported in 24 hours

On Friday, India recorded 774 new Covid-19 cases and 12 fatalities within a 24-hour period. Among the reported deaths, five were in Kerala, four in Karnataka, two in Maharashtra, and one in Uttar Pradesh, according to data from the Union health ministry.

An official from the health ministry mentioned that some states have revised their Covid-19 death data, leading to a sudden increase in reported numbers. However, there is limited evidence of a corresponding rise in hospitalizations or deaths due to Covid-19.

Until December 5, the daily case count remained in double digits. Subsequently, there was a resurgence attributed to cold weather conditions and the emergence of a new Covid-19 variant known as JN.1.

Five out of 43 samples from Delhi Govt Hospitals declared ‘NSQ’

NMC recognition of Medical Qualifications Regulations 2023 released

Bringing uniformity in the matter of recognition of medical qualifications across the country, the final “National Medical Commission (Recognition of Medical Qualification) Regulations, 2023” have now been published in the official Gazette, around 6 months after the draft of the same had been released in the public domain.

For more details, check out the link given below:

NMC Recognition Of Medical Qualifications Regulations 2023 Released, Details


10 patients die after nurse replaces fentanyl IVs with tap water at US hospital

Ten patients at Asante Rogue Regional Medical Center in Medford, Oregon, reportedly died after a nurse allegedly replaced fentanyl intravenous drips with tap water. The hospital officials, suspecting medication theft, alerted the police last month. Conflicting reports from hospital sources mentioned either nine or ten fatalities related to infections.

Powered by WPeMatico

All PG medical students to work as full-time resident doctors for reasonable working hours: NMC PGMER 2023

New Delhi: The newly notified Post-Graduate Medical Education Regulations (PGMER) 2023 have specified that all post-graduate students will work “reasonable working hours” and they will also get “reasonable time for rest in a day”.

Apart from this, there is also a provision for 20 days of paid casual leave, and five days of academic leave per year. Further, subject to the exigencies of work, post-graduate students will be allowed one weekly holiday, as specified in the new regulations.

Referring to the new regulations, the president of the Post-Graduate Medical Education Board of NMC Dr. Viay Oza explained to PTI, “All these will reduce stress on students. Earlier there was no written provision of leaves.”

However, several doctors have expressed their disappointment with the fact that the new regulations did not specify the weekly working hours for the resident doctors. 

Working Hours for Resident Doctors: 

The Medical Profession is one of the harshest professions when it comes to the time and effort involved. The period of residency requires the full-time presence of the doctors in the hospital, day-in, day-out toppled with various night duties coming in rotation.

Moreover, despite efforts made by the government, the issue of mental health of medical students has remained unaddressed over the years. Doctors undergoing Junior Residency During the period of Postgraduate medical education complain of long work hours, low pay, almost inhuman working conditions, lack of basic necessities, and even lack of a clear structure of what is expected.

Even though there have been efforts in the past to address the long working hours, doctors complain that policy has remained limited to the paper only. The Supreme Court in 1990s had directed the Central Government to form a Uniform Central Residency Scheme defining base for all functioning of resident doctors. 

Consequently, the Central Residency Scheme was introduced in 1992 and it addressed several issues including the number of duty hours done by a resident doctor, the issue of weekly off, accommodation of residents, leave travel concessions, etc.

Under this scheme, it was mentioned that the duty hours for the resident doctors would not exceed 12 hours at a time. It had also offered them with one weekly holiday by rotation.

However, these resident-friendly rules remained only on paper, and resident doctors are still found doing at least 70-80 hours of duty a week. In case of a high workload, the duty hours can further be extended. The situation is worse for clinical branches, where certain weeks the work hours can even reach 100 hours.

Previously, NMC had taken cognisance of the issue of mental health of PG medical students. In this regard, earlier, the medical colleges had been directed by the Commission to ensure adequate rest, weekly off, counselling for those who are under stress, arranging Yoga sessions on a regular basis, sanctioning leave when required, and respecting their dignity by providing a positive conducting working environment. 

Medical Dialogues had earlier reported that last year there were reports that NMC was planning to introduce new rules to ensure that PG medical students do not have to work more than 48 hours a week and are given weekly off and proper time to rest.

Also Read: 48-hour work week on cards for resident doctors? Policymakers Claim Matter under consideration

PGMER 2023: 

Finally, the PGMER 2023 was notified in the official Gazette on 29.12.2023, and addressing the issue of resident doctors it mentioned, “All post-graduate students will work as full-time resident doctors. They will work for reasonable working hours and will be provided reasonable time for rest in a day.”

Several doctors have expressed their disappointment over the fact that the working hours for the PG doctors have not been defined by NMC. Commenting on the matter, the president of the Federation of Resident Doctors Association (FORDA) Dr. Aviral Mathur told Medical Dialogues, “We recently met the Honourable Health Minister and explained to him the issue. We said that there should be a bracket.”

He opined that the working hours for the residents should not exceed 72 hours per week adding that it means that the residents will have to work around 12 hours per day. 

Referring to the new regulations prescribing “reasonable working hours”, Dr. Mathur added, “What is “reasonable” is a very subjective thing. What is reasonable for you might not be reasonable for me.”

He expressed that there should have been a quantum defined under the regulations clarifying the bare minimum number of working hours for the residents to complete their course. FORDA has been raising the issue for a long time, he mentioned adding that if this issue gets resolved, the cases of mental illness, and suicides might also decrease.

Recently FORDA met the Union Health Minister Mansukh Mandaviya. Addressing the issue of working hours, the association mentioned in a Release, “We advocated for the implementation of a stringent advisory on working duty hours, emphasizing the necessity to cap the maximum number of hours, and we appreciate the Minister’s commitment to ensuring the well-being of medical professionals.”

Leaves for PG Residents: 

The new regulations have also specified that post-graduate medical students will get a minimum of 20 days of paid leave (casual leave) per year. Apart from this, under these new regulations, doctors will also be allowed weekly holidays.

“Subject to exigencies of work, post-graduate students will be allowed one weekly holiday,” mentioned the regulations. Further, the resident doctors will be given maternity leave and paternity leave as per Government rules and regulations.

There are also provisions for paid leaves for the PG medicos. However, the National Medical Commission (NMC) has clearly specified in the new PGMER 2023 that if a candidate avails leaves more than the permitted number of days, his/her term shall be extended by the same number of days to complete the training period.

Concerning the eligibility to appear in the examination, the regulations mentioned that the candidates can appear in the examination with 80% attendance.

Pointing out that earlier there was no written provision for leaves, NMC PG Board’s president Dr. Vijay Oza explained to PTI that all these will reduce stress on students.

Referring to the issue, Dr. Mathur, the President of FORDA told Medical Dialogues, “We have mixed opinion. We welcome the move. At least they have defined the number of leaves. Previously individual institutions used to specify the number of leaves in their curriculums.”

“20 leaves coupled with 5 academic leaves makes it around 2 leaves per month,” he explained, adding that the association is planning to write communications to the authorities raising the issue of working hours, maternity leave, and other important issues.

Other Aspects of PGMER 2023: 

The regulations also stipulate that it will be mandatory for the college to provide appropriate residential accommodation to post-graduate students. However, it will not be mandatory for the post-graduate students to stay in the hostel.

According to the new regulations, once a medical college is granted permission to start PG courses or seats, the course will be treated as recognised for registration of qualification for students. This will solve many difficulties faced by students to register their degree after passing their postgraduate examinations, Oza said.

“The new regulations will also clear the uncertainty that the students faced on whether these courses will be recognised by the NMC or not,” an official source said.

According to the new regulations, the existing NEET-PG examination will continue till the proposed National Exit Test (NExT) becomes operational for PG admission.

“The NMC after consideration the comments and suggestions of various stakeholders and detailed in-house discussion unveiled groundbreaking reforms in post-graduate medical education, aimed at fostering quality, ethical practice, and inclusivity within the medical fraternity,” Dr. Oza informed PTI.

“These reforms encompass various critical aspects of post-graduate medical training and aim to enhance the standards of education and practice nationwide,” he said.

Under the new regulations, the undergraduate medical college can start postgraduate courses in the third year now. Previously it was from the fourth year in clinical specialties, Dr. Oza said.

Existing or proposed non-teaching hospitals owned and managed by the government can start post-graduate courses without having an undergraduate college. This will facilitate governments to start postgraduate medical colleges in smaller government hospitals/district hospitals, he said. There will be a minimum standard requirement document that will prescribe requirements of infrastructure, faculty clinical material etc for postgraduate institutes.

“All students will have to undergo courses in research methodology, ethics and cardiac life support skills,” Dr. Oza further mentioned.

“For better implementation of these regulations, there is provision of penalty clause which includes monetary penalty, reduction in number of seats( admission capacity) or complete stoppage of admissions,” he stated.

The regulations continue to prohibit the migration of students from one medical institution to another. Additionally, seat reservations in medical colleges for various categories will align with the prevailing laws in states and Union territories.

Reservation of seats shall be as per applicable laws prevailing in states and Union territories. Five per cent reservations will be for candidates with benchmark disabilities.

Also Read: 5 Points about Central Residency Scheme all Doctors Should know

Powered by WPeMatico

Hospitals Deny Admission: Four doctors under Delhi Govt scanner after 47-year-old man succumbs to injuries

New Delhi: Following allegations that an accused patient succumbed to his injuries after being denied treatment at four government hospitals, the state health department has advised implementing disciplinary actions and issuing suspensions to the four doctors associated with Guru Tegh Bahadur (GTB) Hospital and Lok Nayak Hospital in connection with the case. 

The four doctors have been recommended for suspension after it was found that they allegedly denied treatment to the patient, even though there were beds available at the hospitals.

According to a senior health department official, the recommendation of the four doctors from the two hospitals will be sent to the National Capital Civil Services Authority (NCCSA) for further approval. Upon approval, appropriate action will be taken against the doctors.

Also read- Denied Treatment At 3 Govt Hospitals: Delhi Man Succumbs To Injuries, Health Minister Seeks Explanation

NCCSA is an administrative authority that manages the Civil Services in Delhi. The authority is a three-member committee including- the Chief Minister of Delhi, the Chief Secretary and the Principal Home Secretary.

As per an Indian Express news report, the incident has prompted the health department to take swift action against the management of the two hospitals. Censuring the hospitals, the department has directed the Chief Medical Officers (CMOs) concerned to submit a detailed report on the matter. 

The report is expected to include information on when the patient arrived at the hospital, the attending doctor, the patient’s wait for treatment, CCTV footage, and the doctor allegedly responsible for denying treatment and admission.

Medical Dialogues team recently reported that the Delhi Health Minister Saurabh Bharadwaj on Wednesday said the city government asked for an explanation from three state-run hospitals regarding the allegations that he could have saved had the Dilli Ke Farishte scheme been functional. A 47-year-old man died of injuries he suffered after jumping out of a moving police van early on Wednesday, a senior officer said.

Pramod was arrested after a 21-year-old woman alleged that he had molested her in an inebriated state and was taken to four government hospitals by the police personnel due to the unavailability of beds or equipment at the facilities, he added.

The minister said that if the ‘Farishte Dilli Ke’ scheme had been fully functional, the man could have been taken to a nearby private hospital having the requisite medical services and there would have been fair chances of him surviving.

The patient was allegedly refused admission by three Delhi government hospitals namely GTB Hospital, JPC Hospital and Lok Nayak Hospital and one central government hospital, namely RML Hospital.

In addition, the health department also plans to escalate the issue further by informing the Delhi Medical Council (DMC) about the incident.

“The patient was first taken to JPC hospital where he was intubated and sent to GTB…GTB Hospital then sent him to LNJP….One of the hospitals refused to give the patient even a stretcher to lie on while waiting for a doctor. This is a basic facility one hospital has to provide in emergency cases…We also got information that the hospitals had vacant beds and despite that, they refused to admit the patient…Be it an accused or any other person, a hospital should provide treatment to people from any background…” said the source of the Daily. 

Also read- Patient Dies Due To Lack Of Oxygen: NHRC Directs Bihar Govt To Submit Report In Four Weeks

Powered by WPeMatico

Medical Bulletin 6/January/2024

Here are the top medical news of the day:

Even in midlife, disrupted sleep tied to memory, thinking problems later on

People who have more disrupted sleep in their 30s and 40s may be more likely to have memory and thinking problems a decade later, according to new research published in the January 3, 2024, online issue of Neurology, the medical journal of the American Academy of Neurology. The study does not prove that sleep quality causes cognitive decline. It only shows an association.

“Given that signs of Alzheimer’s disease start to accumulate in the brain several decades before symptoms begin, understanding the connection between sleep and cognition earlier in life is critical for understanding the role of sleep problems as a risk factor for the disease,” said study author Yue Leng, PhD, of the University of California, San Francisco. “Our findings indicate that the quality rather than the quantity of sleep matters most for cognitive health in middle age.”

The study involved 526 people with an average age of 40. They were followed for 11 years.

Reference: Even in midlife, disrupted sleep tied to memory, thinking problems later on; AMERICAN ACADEMY OF NEUROLOGY; Neurology

Is radon linked to health condition other than lung cancer?

Radon, a naturally occurring radioactive gas produced when metals like uranium or radium break down in rocks and soil, is a known cause of lung cancer. Now new research has found exposure to high levels of this indoor air pollutant is associated with an increased risk of another condition in middle age to older female participants with ischemic stroke. The study is published in the January 3, 2024, online issue of Neurology, the medical journal of the American Academy of Neurology. Ischemic stroke is caused by a blockage of blood flow to the brain and is the most common type of stroke.

The condition, called clonal hematopoiesis of indeterminate potential (CHIP), develops when some hematopoietic stem cells, the building blocks for all blood cells, undergo genetic mutations as a person ages. Cells with such mutations replicate more quickly than cells without them. Previous research has shown people with CHIP may have a higher risk of blood cancers like leukemia and cardiovascular disease including stroke.

The study involved 10,799 female participants with an average age of 67. Approximately half of participants had a stroke or blood clots.

Reference: Is radon linked to health condition other than lung cancer?; AMERICAN ACADEMY OF NEUROLOGY

Using the body’s own cells to treat traumatic brain injury

More than a million people in the US suffer from a traumatic brain injury (TBI) every year, about 230,000 of them are hospitalized, and almost 70,000 die from TBI-related causes. There is currently no treatment for the damage caused to brain tissue during a TBI, beyond managing a patient’s symptoms. One of the main drivers of TBI-caused damage is a runaway inflammatory cascade in the brain.

Scientists have created a new treatment for traumatic brain injury (TBI) that shrank brain lesions by 56% and significantly reduced local inflammation levels in pigs. The new approach leverages macrophages, a type of white blood cell that can dial inflammation up or down in the body in response to infection and injury.

Reference: Using the body’s own cells to treat traumatic brain injury; PNAS Nexus

Powered by WPeMatico